Structure Therapeutics (NASDAQ:GPCR) Trading Down 7.8%

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price was down 7.8% during trading on Tuesday . The company traded as low as $36.47 and last traded at $36.47. Approximately 238,286 shares were traded during mid-day trading, a decline of 71% from the average daily volume of 828,156 shares. The stock had previously closed at $39.55.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on GPCR shares. JMP Securities restated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Friday, May 10th. BMO Capital Markets lifted their target price on Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, July 1st. Finally, JPMorgan Chase & Co. started coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $85.25.

Structure Therapeutics Trading Down 7.4 %

The stock has a market cap of $1.71 billion, a PE ratio of -48.03 and a beta of -3.59. The company has a fifty day moving average of $42.26 and a 200-day moving average of $41.23.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. As a group, research analysts anticipate that Structure Therapeutics Inc. will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of large investors have recently made changes to their positions in GPCR. Principal Financial Group Inc. purchased a new stake in Structure Therapeutics during the 2nd quarter valued at approximately $6,489,000. Mather Group LLC. purchased a new stake in Structure Therapeutics during the 2nd quarter valued at approximately $214,000. Teachers Retirement System of The State of Kentucky raised its stake in Structure Therapeutics by 17.8% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock valued at $589,000 after acquiring an additional 2,077 shares during the last quarter. Virtu Financial LLC purchased a new stake in Structure Therapeutics during the 1st quarter valued at approximately $308,000. Finally, RA Capital Management L.P. raised its stake in Structure Therapeutics by 210.2% during the 1st quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock valued at $64,734,000 after acquiring an additional 1,023,530 shares during the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.